CODOX-M/IVAC regimen: Difference between revisions
No edit summary |
No edit summary |
||
Line 5: | Line 5: | ||
{{SK}}CODOX-M/IVAC Regimen; Cyclophosphamide-Oncovin-Doxorubicin-Methotrexate/Ifosfamide, VePesid, AraC Regimen; McGrath Regimen | {{SK}}CODOX-M/IVAC Regimen; Cyclophosphamide-Oncovin-Doxorubicin-Methotrexate/Ifosfamide, VePesid, AraC Regimen; McGrath Regimen | ||
==Overview== | ==Overview== | ||
{{PAGENAME}} refers to a regimen consisting of [[cyclophosphamide]], [[vincristine]], [[doxorubicin]] and high-dose [[methotrexate]] (CODOX-M) alternating with [[ifosfamide]], [[etoposide]] and high-dose [[cytarabine]] (IVAC), used as a treatment for aggressive forms of [[non-Hodgkin's lymphoma]]; also used as primary treatment for AIDS-related and high-risk [[Burkitt's lymphoma]]. Intrathecal [[cytarabine]] and [[methotrexate]] are included in this regimen as either prophylaxis or treatment for central nervous system (CNS) involvement. | {{PAGENAME}} refers to a regimen consisting of [[cyclophosphamide]], [[vincristine]], [[doxorubicin]] and high-dose [[methotrexate]] (CODOX-M) alternating with [[ifosfamide]], [[etoposide]] and high-dose [[cytarabine]] (IVAC), used as a treatment for aggressive forms of [[non-Hodgkin's lymphoma]]; also used as primary treatment for AIDS-related and high-risk [[Burkitt's lymphoma]]. Intrathecal [[cytarabine]] and [[methotrexate]] are included in this regimen as either prophylaxis or treatment for central nervous system (CNS) involvement.<ref>{{Cite web | title = NCI Thesaurus | accessdate = | url = http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C63448}}</ref> | ||
==Regimen== | ==Regimen== | ||
Revision as of 19:31, 11 March 2015
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords:CODOX-M/IVAC Regimen; Cyclophosphamide-Oncovin-Doxorubicin-Methotrexate/Ifosfamide, VePesid, AraC Regimen; McGrath Regimen
Overview
CODOX-M/IVAC regimen refers to a regimen consisting of cyclophosphamide, vincristine, doxorubicin and high-dose methotrexate (CODOX-M) alternating with ifosfamide, etoposide and high-dose cytarabine (IVAC), used as a treatment for aggressive forms of non-Hodgkin's lymphoma; also used as primary treatment for AIDS-related and high-risk Burkitt's lymphoma. Intrathecal cytarabine and methotrexate are included in this regimen as either prophylaxis or treatment for central nervous system (CNS) involvement.[1]
Regimen
CCyclophosphamide
VVincristine
DOXDoxorubicin
MMethotrexate
IIfosfamide
Eetoposide
CCytarabine
Indications
- AIDS-related and high-risk Burkitt's lymphoma